Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Repurposed agents in the Alzheimer’s disease drug development pipeline

Open access
Bauzon, Justin, Lee, Garam, Cummings, Jeffrey · 2020 · Alzheimer's Research & Therapy

Abstract

Background: Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the pharmaceutical development process is both time-consuming and costly. Drug repurposing provides an opportunity to accelerate this process by investigating the AD-related effects of agents approved for other indications. These drugs have known safety profiles, pharmacokinetic characterization, formulations, doses, and manufacturing processes. Methods: We assessed repurposed AD therapies represented in Phase I, Phase II, and Phase III of the current AD pipeline as registered on ClinicalTrials.gov as of February 27, 2020. Results: We identified 53 clinical trials involving 58 FDA-approved agents. Seventy-eight percent of the agents in trials had putative disease-modifying mechanisms of action. Of the repurposed drugs in the pipeline 20% are hematologic-oncologic agents, 18% are drugs derived from cardiovascular indications, 14% are agents with psychiatric uses, 12% are drug used to treat diabetes, 10% are neurologic agents, and the remaining 26% of drugs fall under other conditions. Intellectual property strategies utilized in these programs included using the same drug but altering doses, routes of administration, or formulations. Most repurposing trials were supported by Academic Medical Centers and were not funded through the biopharmaceutical industry. We compared our results to a European trial registry and found results similar to those derived from ClinicalTrials.gov. Conclusions: Drug repurposing is a common approach to AD drug development and represents 39% of trials in the current AD pipeline. Therapies from many disease areas provide agents potentially useful in AD. Most of the repurposed agents are generic and a variety of intellectual property strategies have been adopted to enhance their economic value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-020-00662-x

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Classification of repurposed agents by their FDA-approved indications (ClinicalTrials.gov as of February 27, 2020)
Fig. 1 Classification of repurposed agents by their FDA-approved indications (ClinicalTrials.gov as of February 27, 2020)CC BY · PubMed Central
Fig. 2 Percentage of repurposed agents currently under study by mechanisms of action (ClinicalTrials.gov as of February 27, 2020)
Fig. 2 Percentage of repurposed agents currently under study by mechanisms of action (ClinicalTrials.gov as of February 27, 2020)CC BY · PubMed Central
Fig. 3 Classification of the therapeutic areas of repurposed agent currently under study (ClinicalTrials.gov as of February 27, 2020)
Fig. 3 Classification of the therapeutic areas of repurposed agent currently under study (ClinicalTrials.gov as of February 27, 2020)CC BY · PubMed Central
Fig. 4 Repurposing trials over time in the Alzheimer’s disease drug development pipeline (2016–2020)
Fig. 4 Repurposing trials over time in the Alzheimer’s disease drug development pipeline (2016–2020)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 77

Metadata

Authors
Bauzon, J., Lee, G., & Cummings, J.
Affiliations
  • University of Nevada, Las Vegas (US)
  • Cleveland Clinic (US)
Corresponding author
Cummings, Jeffrey
Venue
Alzheimer's Research & Therapy
Published
2020-08-17
Volume
12
Issue
1
Pages
98-98
ISSN
1758-9193 (ISSN-L)
OpenAlex
W3049299998
Cited by
77
References
55
Citations by year
2026: 8 · 2025: 9 · 2024: 11 · 2023: 12 · 2022: 16 · 2021: 20 · 2020: 1
FWCI
7.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of General Medical Sciences (P20GM109025)
  • National Institute of Neurological Disorders and Stroke (U01NS093334)
  • National Institute on Aging (R01AG053798)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, drug repurposing, clinical trials, drug development pipeline, FDA-approved drugs, disease-modifying therapy, intellectual property strategy, clinical trial funding, ClinicalTrials.gov
MeSH terms
Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repurposed agents in the Alzheimer’s disease drug development pipeline. https://app.cochat.ai/papers/10.1186/s13195-020-00662-x
The paper
Bauzon, J., Lee, G., & Cummings, J. (2020). Repurposed agents in the Alzheimer’s disease drug development pipeline. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00662-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.